Unlabelled: Like other previous treatments and approaches, sorafenib, an antiangiogenic drug, failed to show any benefit in the adjuvant setting for hepatocellular carcinoma in a large clinical trial. We discuss reasons and implications of these negative results and the implications for clinical practice and future research.
Trial Registration: ClinicalTrials.gov: NCT00692770 . Registered 5 June 2008. This study has been completed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124225 | PMC |
| http://dx.doi.org/10.1186/s13063-016-1675-8 | DOI Listing |
Publication Analysis
Top Keywords
hepatocellular carcinoma
8
adjuvant therapies
4
therapies advanced
4
advanced hepatocellular
4
carcinoma moving
4
moving forward
4
forward storm
4
storm unlabelled
4
unlabelled previous
4
previous treatments
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!